A cancer diagnosis changes many things. Whether it ends your ability to get life insurance is not automatically one of them. Cancer underwriting is among the most complex areas in life insurance — outcomes vary dramatically by cancer type, stage, treatment protocol, and the time elapsed since treatment — but coverage of some kind is available for almost every cancer survivor. This guide explains what to expect based on the most common cancer types and stages.
Underwriters are not evaluating whether you had cancer. They are evaluating the probability that the cancer returns or that you experience cancer-related complications. Time since successful treatment, cancer type, and stage are the three variables that matter most. A 10-year survivor of early-stage breast cancer and a person in active chemotherapy for an aggressive lymphoma require entirely different underwriting approaches.
During Active Cancer Treatment
With very few exceptions, traditional life insurance underwriting will not issue a policy while you are in active cancer treatment — chemotherapy, radiation, immunotherapy, or surgical treatment for cancer. The clinical picture is incomplete and the risk is too uncertain to price. Most carriers will postpone the application until treatment is complete and some period of monitoring has passed.
During this period, two options provide coverage:
- Employer group life insurance — if you are employed and your employer offers group life coverage, this is available to you regardless of your health status. This is often the most cost-effective coverage available during treatment.
- Guaranteed issue life insurance — accepts all applicants regardless of health history. Coverage is limited (typically $2,000–$25,000) and there is a 2-year graded benefit period, but it provides some financial protection during a time when other options are closed.
Coverage Availability by Cancer Type
Non-Melanoma Skin Cancer (Basal Cell and Squamous Cell Carcinoma)
This is the most favourable cancer type for life insurance underwriting. Basal cell carcinoma and squamous cell carcinoma — the most common cancers in the United States — are typically approvable at standard or near-standard rates with no waiting period after documented, successful treatment. Underwriters treat these as dermatological conditions rather than systemic cancers because they rarely metastasise and have near-perfect cure rates when detected and treated early.
Thyroid Cancer (Early Stage)
Papillary thyroid carcinoma (the most common type) has a 5-year survival rate exceeding 99% for localised disease. After treatment and 2–3 years of clean follow-up scans and labs, many carriers will consider traditional underwriting at rated or standard rates. The specific rating depends on stage and whether the cancer spread to lymph nodes.
Breast Cancer
Among the most complex underwriting situations. Key variables: hormone receptor status (ER/PR positive cancers generally have more favourable long-term outcomes), HER2 status, stage and grade, and treatment completeness. Early-stage, hormone-positive breast cancer with a 2–5 year remission period is often insurable at some carriers, with ratings depending on stage. Higher-stage or triple-negative breast cancer requires longer remission periods — typically 5–10 years — before traditional underwriting becomes available.
Prostate Cancer
One of the more favourable cancers for underwriting among active treatment survivors. Gleason score (the pathological grading system), PSA levels, and treatment type all factor in. Low Gleason score prostate cancer (6 or below) treated with surgery or radiation can often be underwritten at standard or modestly rated rates after 1–2 years of remission with normal PSA. Higher Gleason scores require longer remission periods.
Colorectal Cancer
Stage is the dominant variable. Stage I colorectal cancer in full remission for 3–5 years is typically insurable at rated rates at some carriers. Stage II and III require longer remission periods (5–10 years). Stage IV (metastatic) with remission — while increasingly achievable with modern treatment — remains very difficult to underwrite traditionally and may require 10+ years of documented full remission.
Melanoma
Underwritten more conservatively than non-melanoma skin cancers despite being a skin cancer. Stage I (in situ) melanoma with documented excision and no recurrence: typically insurable at rated rates after 3–5 years. Stage II melanoma: typically 7–10 years remission before traditional underwriting. Stage III or IV: extremely conservative, often 10+ years or decline.
Blood Cancers (Lymphoma, Leukaemia)
Outcome varies significantly by type. Hodgkin lymphoma, with some of the best long-term outcomes of any cancer, may be underwritten after 5–7 years of complete remission. Non-Hodgkin lymphoma and leukaemia require longer remission periods and result in higher ratings given the heterogeneity of these cancers.
Typical Remission Requirements by Cancer Category
| Cancer Category | Typical Minimum Remission (before traditional UW) | General Rate Expectation |
|---|---|---|
| Non-melanoma skin cancer | None (with documented treatment) | Standard to Preferred |
| Early thyroid cancer | 2–3 years | Rated (Table 2–4) |
| Early-stage prostate (low Gleason) | 1–2 years | Standard to Rated |
| Early breast cancer (hormone positive) | 2–5 years | Rated (Table 4–8) |
| Early colorectal (Stage I) | 3–5 years | Rated |
| Stage I melanoma | 5 years | Rated |
| Hodgkin lymphoma | 5–7 years | Rated to Standard |
| Higher-stage solid tumours | 7–10+ years | Rated to Decline |
| Active treatment or recent recurrence | Not underwritten | Guaranteed issue only |
Practical Steps for Cancer Survivors
- Work with an impaired risk specialist, not a direct carrier. Cancer underwriting is highly carrier-specific. One carrier may decline an applicant that another rates at Table 6. An impaired risk specialist submits informal inquiries to multiple carriers — preventing formal denials from accumulating on your MIB record — and routes your application to the carrier most likely to approve it at the best rate for your specific cancer history.
- Gather your medical records. Your application should include the pathology report from your diagnosis (cancer type, stage, grade), your treatment records (surgery, radiation, chemotherapy protocols), and your most recent oncology follow-up notes confirming remission status.
- Get coverage during the waiting period. If you are in the remission period before traditional underwriting becomes available, employer group coverage and guaranteed issue provide meaningful interim protection. Do not wait until you qualify for traditional coverage if you have dependants now.
- Reapply as time passes. A decline today is not necessarily a decline in three years. If you were declined or postponed because you were within the waiting period, apply again after the appropriate remission period has passed. Document your clean follow-up care during the interim.
